NanoViricides Inc. has announced significant progress with its clinical lead drug, NV-387, which has demonstrated potent activity against the Measles virus in both cell culture studies and a humanized animal model. Results from preclinical studies showed that NV-387 treatment extended survival in a lethal Measles infection model by 130%, from 7.4 days in untreated animals to 17 days in treated ones. NV-387 has also completed Phase I human trials, with no reportable adverse events, confirming its safety and tolerability in healthy subjects. The company is now positioned to support emergency use applications of NV-387 for Measles patients under FDA guidelines and is open to Physician's Investigator-Initiated INDs for urgent cases. NV-387 is formulated as oral gummies, offering a potential advantage for patients with Measles-related throat irritation. The drug is also advancing into a Phase II clinical trial for the evaluation of safety and effectiveness in treating MPox. These results have already been presented in company communications and interviews.